Dengue: A continuing challenge for molecular biology

Current Opinion in Infectious Diseases

Volumn 11, Issue 3, 1998, Pages 319-324

  Jacobs, Michael Graham ^a   Young, Paul Robert ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; RECEPTOR; VIRUS PROTEIN;

DENGUE; DENGUE VIRUS; IMMUNE RESPONSE; MOLECULAR BIOLOGY; PATHOGENESIS; REVIEW;

EID: 0031868717     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199806000-00009     Document Type: Review

References (47)

1. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-481.
2. Dengue in the Americas - time to talk [editorial]. Lancet 1997; 350:455
3. Rico-Hesse R, Harrison LM, Alba Salas R, Tovar D, Nisalak A, Ramos C, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230:244-251. Comparison of nucleotide sequences from the E/NS1 region of the dengue virus genome allows the evolutionary relationships of dengue virus strains to be determined. Using this approach, this paper shows that the introduction of southeast Asian strains of dengue 2 into the western hemisphere is associated with the appearance of DHF/DSS in this region. Understanding the basis for the variations in virulence between different strains of dengue virus will be important for devising vaccine strategies targeted at the prevention of DHF/DSS.
4. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis and prevention. J Pediatr 1997; 131:516-524.
5. Hales S, Weinstein P, Woodward A. Dengue fever epidemics in the South Pacific: driven by El Niño southern oscillation? Lancet 1996; 348:1664-1665.
6. Sehgal R. Dengue fever and El Niño. Lancet 1997; 349:729.
7. Jetten TH, Focks DA. Potential changes in the distribution of dengue transmission under climate warming. Am J Trop Med Hyg 1997; 57:285-297.
8. Schwartz E, Mendelson E, Sidi Y. Dengue fever among travelers. Am J Med 1996; 101:516-520.
9. Jelinek T, Dobler G, Holscher M, Loscher T, Nothdurft HD. Prevalence of infection with dengue virus among international travelers. Arch Intern Med 1997; 157:2367-2370.
10. Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol 1996; 70:8765-8772. This directly demonstrates that E mediates binding to target cells. Detailed examination of the binding of partial-length recombinant E locates the binding motif to between amino acids 281 and 423. Definition of the molecular basis of the virus-cell receptor interaction may help future vaccine and drug development.
11. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997; 3:866-871. In a series of experiments, this paper shows that dengue virus binds selectively to highly sulphated heparan sulphate on target cells via E. Dengue virus serotype 2 was used throughout, but given the sequence homology within the putative binding domain of E, it is likely that this is true for all four serotypes of dengue virus. The elucidation of at least one component of the cellular receptor for dengue is a highly significant step towards a better understanding of the tropism and pathogenesis of dengue virus infection.
12. Putnak JR, Kanesa TN, Innis BL. A putative cellular receptor for dengue viruses. Nat Med 1997; 3:828-829.
13. Salas-Benito JS, del Angel RM. Identification of two surface proteins from C6/36 cells that bind dengue type 4 virus. J Virol 1997; 71:7246-7252.
14. Hayes CG, Halstead SB. Dengue and Japanese encephalitis. Curr Opin Infect Dis 1996; 9:308-312.
15. Mackenzie JM, Jones MK, Young PR. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 1996; 220:232-240.
16. Westaway EG, Mackenzie JM, Kenney MT, Jones MK, Khromykh AA. Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 1997; 71:6650-6661.
17. Muylaert IR, Chambers TJ, Galler R, Rice CM. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology 1996; 222:159-168.
18. Muylaert IR, Galler R, Rice CM. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J Virol 1997; 71:291-298.
19. Lindenbach BD, Rice CM. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication. J Virol 1997; 71:9608-9617. This paper provides strong evidence that NS1 plays a role in early RNA replication, and in doing so demonstrates the power of a method of transcomplementation of defective yellow fever virus using non-cytopathic Sindbis replicons. This technology has enormous potential for future studies of flaviviruses (and other RNA viruses) because it allows viruses with lethal mutations to be propagated so that the precise phenotypic effects of a mutation can then be determined.
20. Sudo K, Matsumoto Y, Matsushima M, Fujiwara M, Konno K, Shimotohno K, et al. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem Biophys Res Commun 1997; 238:643-647.
21. Martin F, Volpari C, Steinkuhler C, Dimasi N, Brunetti M, Biasiol G, et al. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng 1997; 10:607-614.
22. Dimasi N, Martin F, Volpari C, Brunetti M, Biasiol G, Altamura S, et al. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J Virol 1997; 71:7461-7469.
23. Polo S, Ketner G, Levis R, Falgout B. Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast. J Virol 1997; 71:5366-5374.
24. Khromykh AA, Westaway EG. Subgenomic replicons of the flavivirus Kunjin: construction and applications. J Virol 1997; 71:1497-1505.
25. Marianneau P, Cardona A, Edelman L, Deubel V, Despres P. Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J Virol 1997; 71:3244-3249.
26. Mon M, Kurane I, Janus J, Ennis FA. Cytokine production by dengue virus antigen-responsive human T lymphocytes in vitro examined using a double immunocytochemical technique. J Leukocyte Biol 1997; 61:338-345.
27. Hober D, Delannoy AS, Benyoucef S, De GD, Wattre P. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol Immunol 1996; 40:569-573.
28. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 1997; 71:4226-4232. This paper links dengue-infected peripheral blood monocytes and human endothelial cells in an in-vitro model system designed to explore some aspects of the pathogenesis of DHF/DSS. It suggests that TNF-α may be an important mediator of endothelial cell activation during dengue virus infection. The use of similar model systems may yield further interesting clues to the pathogenesis of DHF/DSS, which is especially significant in the absence of an animal model of DHF/DSS.
29. Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yen TM. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol 1997; 110:35-40.
30. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/ adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997; 142:897-916.
31. + cytotoxic T lymphocyte clones. Virology 1997; 234:383-386.
32. Chambers TJ, Tsai TF, Pervikov Y, Monath TP. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 1997; 15:1494-1502. The WHO Global Programme on Vaccines and Immunization promotes and funds research and development of new and improved vaccines against a panel of important infectious pathogens. Dengue virus and Japanese encephalitis virus comprise a focused group within this framework. Regular meetings are held to review progress and this paper clearly and comprehensively reports the state of play as of the end of 1996.
33. Vaughn DW, Hoke CJ, Yoksan S, LaChance R, Innis BL, Rice RM, Bhamarapravati N. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 1996; 14:329-336.
34. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174:1176-1184.
35. Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 1996; 55:504-510.
36. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, Gubler DJ. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine denvative, strain PDK-53. Virology 1997; 230:300-308. Complete sequencing of the genomes of the parental dengue 2 virus 16681 strain and two genetic variants within the PDK-53 attenuated derivative revealed only nine nucleotide differences out of the nearly 11 kb long genome. This low level of nucleotide substitution, coupled with the preparation of infectious clones for each strain, will enable a fairly straightforward site-directed mutagenesis study to identify those changes responsible for the attenuation phenotype. Successful identification of these attenuating mutations should then provide the basis for genetically engineering live attenuated vaccines.
37. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:3930-3937.
38. Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 1996; 70:4162-4166.
39. Starapoli I, Frenkiel MP, Megret F, Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 1997; 15:1946-1954.
40. Sugrue RJ, Fu J, Howe J, Chan YC. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 1997; 78:1861-1866. One of the intriguing observations made in this paper is the apparently efficient cleavage of the C/prM junction of the expressed product. It is this cleavage which leads to the correct maturation of the structural proteins as immunogenic VLPs. Expression of gene cassettes comprising the structural proteins alone have previously met with failure as a consequence of a requirement for viral protease activity supplied by NS2b/3. Presumably no such restrictions occur in yeast cells?
41. Bielfeldt-Ohmann H, Beasley DWC, Fitzpatrick DR, Aaskov JG. Analysis of a recombinant dengue-2 virus dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system. J Gen Virol 1997; 78:2723-2733.
42. Phillpotts RJ, Venugopal K, Brooks T. Immunisation with DNA polynucleotides protects mice against lethal challenge with St Louis encephalitis virus. Arch Virol 1996; 141:743-749.
43. Lin YL, Chen LK, Liao CL, Yeh CT, Ma SH, Chen JL, et al. DNA immunization with Japanese encephalitis virus nonstuctural protein NS1 elicits protective immunity in mice. J Virol 1998; 72:191-200.
44. Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, Porter K, Hayes C. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997; 15:547-552. Immunization with plasmids expressing the dengue-2 virus prM and E proteins were shown to elicit neutralizing antibody in mice, although only after at least three intradermal inoculations. The relatively slow antibody response reported in this paper (not dissimilar to reports of DNA immunization in other systems) highlights a potential problem for future experiments examining the protective efficacy of DNA vaccines for dengue. Dengue virus challenge in mice needs to be performed by the intracranial route and mice older than 6-10 weeks are less susceptible to infection. The mouse model may be confined to studies of immunogenicity with protection subsequently examined in primates.
45. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322-330.
46. Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, Kunentrasai N, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313-321. This study forms part of a multicentre effort designed to characterize the pathophysiology of dengue. By undertaking detailed prospective clinical and laboratory studies of infected children, it is likely significantly to advance knowledge about dengue as more data are published over the next few years. In this report, which addresses simple clinical and hospital laboratory indicators of acute dengue illness, the great potential of this approach is apparent.
47. Tassniyom S, Vasanawathna S, Dhiensiri T, Nisilak A, Chirawatkul A. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial. J Pediatr 1997; 131:525-528. There are very few carefully designed trials of treatment of DHF/DSS. The importance of these is emphasized by the conclusion from this study that AC-17 is not a valuable treatment for DHF/DSS, in contrast to the earlier reports of beneficial effects in less well-designed studies.